# HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer

> **NCT03578406** · PHASE1 · COMPLETED · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 9 (actual)

## Conditions studied

- Cervical Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** HPV E6-specific TCR-T cells

## Key facts

- **NCT ID:** NCT03578406
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-10-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-01-21

## Collaborators

- TCRCure Biopharma Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03578406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03578406, "HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT03578406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*